Join leading experts to discuss how we are ushering in a new era in bladder cancer care on May 28 virtually. Register now.

Bladder cancer is among the top 10 most common cancer types in the world, with approximately 573,000 new cases annually. Men ...

UroGen Pharma ( NASDAQ: URGN) announced on Wednesday that the U.S. FDA has scheduled an Oncologic Drugs Advisory Committee ...

Bladder preservation for bladder cancer requires balancing clinical factors and patient health with a personalized treatment ...

TAR-200 demonstrated a high disease-free survival and bladder preservation rates in BCG-unresponsive, high-risk ...

Congressman Greg Murphy, M.D., is recognizing May as Bladder Cancer Awareness Month. “While most bladder cancers are caught ...

ImmunityBio's ANKTIVA sBLA for papillary bladder cancer was rejected by the FDA despite prior support, prompting the company ...

CG Oncology shared new Phase 3 trial results showing durable responses and strong patient compliance in high-risk bladder ...

Chris Cotton is raising money for cancer centers after being told the day after his 50th birthday that what he thought was a ...

Oncologists at AUA 2025 share promising data, including sasanlimab, cretostimogene grenadenorepvec, and TAR-200 in NMIBC.

Johnson & Johnson (JNJ) posts promising Phase 2b trial results for its chemotherapy releasing system TAR-200 in bladder ...

A 50-year-old resident of Cheshire, who mistook his initial symptoms of bladder cancer to be a UTI, drank cranberry juice as ...